NYSE · Financial Statements

Ibere Pharmaceuticals (IBER) Financial Statements

$10.18 NYSE: IBER Market Cap $175.60M

Ibere Pharmaceuticals most recently reported annual revenue of $0, net profit of $2.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Annual Financials (USD)

Metric20202021
Revenue—$0
Operating Profit—$-1.0M
Net Profit—$2.0M
EPS—$0.34
Op Margin——

Balance Sheet (USD)

Metric20202021
Total Assets$1.0M$139.0M
Total Liabilities$1.0M$12.0M
Cash$0$0
Borrowings$0$0

Cash Flow (USD)

Metric20202021
Operating Cash Flow—$-1.0M
Investing Cash Flow—$-138.0M
Financing Cash Flow—$139.0M
Net Cash Flow—$0
Free Cash Flow$0$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-174.45
FCF Yield-0.49%
Quick Ratio1.86
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksNYSE High ROE StocksAll stock screens
IBER Overview IBER Dividend Run Stock Screener